NCT05606263View on ClinicalTrials.gov

Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

November 30, 2025

Conditions
Cervical Cancer
Interventions
DRUG

Caldonirimab and Nimotuzumab

Subjects will receive caldonirimab (6mg/Kg, q2w) until disease progression or for a maximum of 12 months, and Nimotuzumab (400mg/time, q2w) for a total of 8 cycles

Trial Locations (1)

710061

RECRUITING

The First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an

All Listed Sponsors
lead

Xi'an Jiaotong University

OTHER